These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15229152)

  • 1. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.
    Irving JA; O'Brien S; Lennard AL; Minto L; Lin F; Hall AG
    Clin Chem; 2004 Jul; 50(7):1233-7. PubMed ID: 15229152
    [No Abstract]   [Full Text] [Related]  

  • 2. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
    Soverini S; Martinelli G; Amabile M; Poerio A; Bianchini M; Rosti G; Pane F; Saglio G; Baccarani M; ;
    Clin Chem; 2004 Jul; 50(7):1205-13. PubMed ID: 15107311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
    Nardi V; Azam M; Daley GQ
    Curr Opin Hematol; 2004 Jan; 11(1):35-43. PubMed ID: 14676625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.
    Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Cupri A; Consoli C; Messina L; Tirrò E; Messina A; Di Raimondo F
    Leuk Res; 2009 Sep; 33(9):e157-8. PubMed ID: 19406471
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.
    Cowan-Jacob SW; Guez V; Fendrich G; Griffin JD; Fabbro D; Furet P; Liebetanz J; Mestan J; Manley PW
    Mini Rev Med Chem; 2004 Mar; 4(3):285-99. PubMed ID: 15032675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
    Barthe C; Gharbi MJ; Lagarde V; Chollet C; Cony-Makhoul P; Reiffers J; Goldman JM; Melo JV; Mahon FX
    Br J Haematol; 2002 Oct; 119(1):109-11. PubMed ID: 12358910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
    Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [State of the art in the treatment of chronic leukemias].
    Ohnishi K
    Rinsho Ketsueki; 2006 Apr; 47(4):278-86. PubMed ID: 16715962
    [No Abstract]   [Full Text] [Related]  

  • 10. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
    Sawyers CL
    Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
    Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
    Nimmanapalli R; Bhalla K
    Curr Opin Oncol; 2002 Nov; 14(6):616-20. PubMed ID: 12409651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
    von Bubnoff N; Veach DR; van der Kuip H; Aulitzky WE; Sänger J; Seipel P; Bornmann WG; Peschel C; Clarkson B; Duyster J
    Blood; 2005 Feb; 105(4):1652-9. PubMed ID: 15459011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
    Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
    Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
    Donato NJ; Wu JY; Stapley J; Lin H; Arlinghaus R; Aggarwal BB; Shishodia S; Albitar M; Hayes K; Kantarjian H; Talpaz M
    Cancer Res; 2004 Jan; 64(2):672-7. PubMed ID: 14744784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
    Chahardouli B; Zaker F; Mousavi SA; Saffari Z; Nadali F; Ostadali M; Ghadimi H; Alimoghaddam K; Ghavamzade A; Rostami S
    Hematology; 2013 Nov; 18(6):328-33. PubMed ID: 23676790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 18. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
    White DL
    Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
    [No Abstract]   [Full Text] [Related]  

  • 19. STI571 (imatinib mesylate): the tale of a targeted therapy.
    Thambi P; Sausville EA
    Anticancer Drugs; 2002 Feb; 13(2):111-4. PubMed ID: 11901302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.